|
Exhibit 10.2
AMENDED AND RESTATED
EXCLUSIVE PATENT LICENSE AGREEMENT
SCOLR PHARMA, INC.
AND
ARCHER-DANIELS-MIDLAND COMPANY
TABLE OF
CONTENTS
| |
|
|
|
|
|
|
|
Page
|
|
|
|
1
|
|
|
|
|
|
2
|
|
|
|
|
|
2
|
|
|
|
|
|
3
|
|
|
|
|
|
3
|
|
|
|
|
|
3
|
|
|
|
|
|
3
|
|
|
|
|
|
3
|
|
|
|
|
|
3
|
|
|
|
|
|
4
|
|
|
|
|
|
5
|
|
|
|
|
|
5
|
|
|
|
|
|
6
|
|
|
|
|
|
6
|
|
|
|
|
|
6
|
|
|
|
|
|
6
|
|
|
|
|
|
7
|
|
|
|
|
|
7
|
|
|
|
|
|
7
|
|
|
|
|
|
8
|
|
|
|
|
|
8
|
|
|
|
|
|
8
|
|
|
|
|
|
8
|
|
|
|
|
|
8
|
|
|
|
|
|
9
|
i
| |
|
|
|
|
|
|
|
9
|
|
|
|
|
|
10
|
|
|
|
|
|
10
|
|
|
|
|
|
11
|
|
|
|
|
|
11
|
|
|
|
|
|
11
|
|
|
|
|
|
12
|
|
|
|
|
|
12
|
|
|
|
|
|
12
|
|
|
|
|
|
12
|
|
|
|
|
|
12
|
|
|
|
|
|
12
|
|
|
|
|
|
12
|
|
|
|
|
|
12
|
|
|
|
|
|
12
|
ii
AMENDED AND
RESTATED
EXCLUSIVE PATENT LICENSE AGREEMENT
THIS AMENDED AND RESTATED EXCLUSIVE PATENT LICENSE AGREEMENT ("
Agreement ") made as of August 10, 2006 by and between
SCOLR Pharma, Inc., a Delaware corporation formerly known as
Nutraceutix, Inc. (hereinafter referred to as " SCOLR "),
and Archer-Daniels-Midland Company, a Delaware corporation
(hereinafter referred to as " ADM ").
W I T N E S S E T H:
WHEREAS, SCOLR and ADM are parties to an Exclusive Patent
License Agreement dated as of March 8, 2002 (the " Existing
Agreement "), pursuant to which SCOLR granted to ADM a license
to manufacture, use, sell and offer to sell Licensed Products and
Inventions (as each such term is defined in the Existing Agreement)
in the Territory (as defined in the Existing Agreement) pursuant to
the terms and conditions set forth in the Existing Agreement;
and
WHEREAS, SCOLR and ADM desire to modify the terms of the license
granted by SCOLR to ADM under the Existing Agreement by amending
and restating the Existing Agreement on the terms hereof.
NOW, THEREFORE, in consideration of the premises and the mutual
agreements contained herein, and other good and valuable
consideration, the receipt and sufficiency of which is hereby
acknowledged by the Parties, and intending to be legally bound
hereby, the Parties agree as follows:
ARTICLE 1
DEFINITIONS
For the purposes of this Agreement, unless the context clearly
or necessarily requires otherwise, the following terms shall have
the meanings set forth below:
-
" Affiliate " of a Party shall mean any company,
corporation, partnership, syndicate or other entity that, directly
or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with, such Party. "
Control " shall mean ownership of fifty-one percent
(51%) or more of the voting rights or equity in the specified
entity.
" Effective Date " shall mean the date when this
Agreement is fully executed by the Parties.
" Improvements " shall mean any discovery, concept, trade
secret, art, clinical data, idea or other information, whether or
not patentable, that relates to or arises out of the subject
matters disclosed in the Licensed Patent, as well as any foreign
patents or foreign patent applications corresponding thereto, and
any continuations, continuations-in-part, divisionals, reissues,
reexaminations, extensions or additions thereof, whether or not for
use in the Licensed Field of Use.
1
-
" Intellectual Property " shall mean all
forms of intellectual property existing on or after the date of
this Agreement under the laws of any state or country, including,
but not limited to, inventions, designs and plants, in each case,
whether or not patentable, patent rights, copyrightable works, mask
works, trademarks, service marks, trade secrets, know-how and trade
dress.
" Knowledge of ADM " shall mean the knowledge of the
corporate officers of ADM and the officers of the ADM Natural
Health & Nutrition Division on the Effective Date.
" Licensed Field of Use " shall mean a sustained release
oral solid dosage form product comprising a nutraceutical, a
dietary supplement or a combination thereof, comprising
isoflavones; provided , that any additional nutraceutical
ingredient or dietary supplement used in such product (excluding
the isoflavones in such product and any nutraceutical ingredient
contained as part of an isoflavone concentrate included in the
specifications set forth in Exhibit 1 ) shall not be present in an
amount of more than 35% of the weight of the product. As used in
this definition, "dietary supplement" means the terms "dietary
supplement" as defined in the Dietary Supplement Health and
Education Act of 1994, as amended, irrespective of whether a
product is manufactured, marketed, sold or used in the United
States.
" Licensed Patent " shall mean United States Patent
Number 6,090,411 and patent rights with respect to Improvements, as
well as rights to any other U.S. or foreign patents or foreign
patent applications corresponding thereto, any continuations,
continuations-in-part, divisionals, reissues, reexaminations,
extensions or additions thereof.
" Licensed Products " shall mean any product or part
thereof in the Licensed Field of Use, the manufacture, use, sale,
offer for sale, or importation of which (i) is covered by one
or more claims of the Licensed Patent or (ii) utilizes an
Improvement invented, conceived, made, developed, discovered, first
reduced to practice or created by SCOLR prior to the Effective
Date.
" Parties " shall mean both SCOLR and ADM, and the "
Party " shall mean either of them.
" Qualified Offering " shall mean the sale of
SCOLR’s capital stock in a transaction that results in net
proceeds to SCOLR (after deduction of fees and expenses related to
such offering) of not less than US$10,000,000.
" Territory " shall mean worldwide.
ARTICLE 2
GRANT OF LICENSE
2.1. SCOLR Licensed Patent . While this Agreement is in
effect, and subject to the terms and conditions hereof, SCOLR
hereby grants to ADM an exclusive, royalty-free license,
2
with the right to grant sublicenses, to
manufacture, have manufactured on its behalf, use, sell and offer
to sell the Licensed Products in the Territory. While this
Agreement is in effect and ADM is performing its obligations
hereunder, SCOLR shall not grant other licenses under the Licensed
Patent in the Territory for the Licensed Field of Use or itself
manufacture, have manufactured, use, sell, market, offer for sale
or import Licensed Products in the Territory. All other rights are
retained by and reserved to SCOLR.
2.2. Improvements . SCOLR shall promptly disclose to ADM
any Improvements that are invented, conceived, made, developed,
discovered, first reduced to practice or created by SCOLR, its
employees or agents, during the term of this Agreement and that
apply to Licensed Products. ADM shall have the option to obtain a
license with respect to the Intellectual Property embodied in any
such Improvements and any patents or patent applications therefor
with respect to the Licensed Field of Use, and if ADM so exercises
its option then the same shall come under this Agreement and be
subject to the terms and provisions hereof. SCOLR may file for
patent protection for any such Improvements as it sees fit at its
cost. If SCOLR fails to pursue patent protection to the extent
desired by ADM, and ADM exercises its option hereunder, then ADM
may pursue such patent protection, at its cost, in the name of
SCOLR after providing SCOLR with thirty (30) days advance
written notice thereof and SCOLR failing to take such action itself
during such period of time. Each Party shall provide cooperation to
the other Party to execute any documents necessary to effectuate
such patent protection. Notwithstanding the foregoing, SCOLR shall
have no obligation to develop any Improvements or seek patent
protection for any such Improvement.
2.3. Termination of Other Rights . Except as set forth in
this Agreement, all other grants, licenses and other rights,
including Intellectual Property rights, granted to ADM pursuant to
the terms of the Existing Agreement are hereby terminated.
ARTICLE 3
PAYMENTS
In consideration for ADM agreeing to amend and restate the
Existing Agreement on the terms hereof, which amendments include
the termination of certain Intellectual Property rights previously
granted by SCOLR to ADM, SCOLR hereby agrees to make the following
payments to ADM:
3.1. Initial Payment . On the Effective Date, SCOLR shall
pay US$200,000 to ADM by wire transfer of immediately available
funds to an account to be designated by ADM.
3.2. Subsequent Payment . On the earlier of (i) the
one year anniversary of the Effective Date, or (ii) the date
on which SCOLR consummates a Qualified Offering, SCOLR shall pay
US$250,000 to ADM by wire transfer of immediately available funds
to an account to be designated by ADM.
3.3. Books and Records . ADM acknowledges that SCOLR has
certain royalty obligations to third parties arising out of the
Licensed Patent. Accordingly, ADM shall keep and retain, for not
less than three (3) years, full, complete and accurate books
of account and records
3
relating to the manufacture, use and sale or
other disposition of the Licensed Products by or for ADM in such
detail as will enable SCOLR to evidence what royalties are payable
to any such third party. Such books and records shall be consistent
with ADM’s overall financial statements and in compliance
with generally accepted accounting principles and practices in the
United States, consistently applied. ADM shall, during business
hours and upon reasonable notice, permit an independent accounting
firm (retained by SCOLR) that has entered into a secrecy agreement
reasonably acceptable to the parties access to such books and
records for the sole purpose of verifying any such royalty
obligations of SCOLR. The verification will take place at
SCOLR’s expense.
ARTICLE 4
INFRINGEMENT
4.1 Notification . In the event that ADM or SCOLR has
reason to believe that a third party is infringing upon the
Licensed Patent, such party shall promptly notify the other party
in writing of such alleged infringement.
4.2 Infringement Actions .
-
(a) Upon notification of potential infringement pursuant to
Section 4.1 , ADM shall have the option to enforce the
Licensed Patent in the Licensed Field of Use itself or request
SCOLR to enforce the Licensed Patent in the Licensed Field of Use.
In the event ADM elects to enforce the Licensed Patent, the
reasonable costs of such action shall be borne by ADM. In the event
ADM elects to have SCOLR enforce the Licensed Patent, ADM shall
provide SCOLR with written notice thereof, and to the extent deemed
reasonably necessary by ADM, SCOLR shall commence an infringement
action, in which event the reasonable costs of such action shall be
borne equally by the Parties.
(b) Notwithstanding Section 4.2(a) , SCOLR shall
have the right (but not the obligation) to enforce the Licensed
Patent in the Licensed Field of Use if ADM opts to enforce the
Licensed Patent pursuant to Section 4.2(a) but, in the
reasonable determination of SCOLR after not less than 30
days’ prior written notice to ADM, ADM has failed to take
reasonable action to enforce the Licensed Patent. In the event that
SCOLR elects to enforce the Licensed Patent, the reasonable costs
of such action shall be borne by SCOLR.
(c) The benefits of any damages recovered from an action
relating to enforcement of the Licensed Patent in the Licensed
Field of Use (after each Party recovers any share of its costs of
such action) shall be distributed to ADM.
(d) In any such infringement action, the Party commencing the
action (the " Participating Party ") shall keep the other
Party (the " Non-participating Party ") advised of the
progress of the litigation and shall provide the Non-participating
Party with drafts of the pleadings, discovery, motions, and briefs
prior to filing for the Non-participating Party’s review and
comment. In addition, the Participating Party shall consult with
the Non-participating Party with regard to every material decision
required to be made during the litigation. The
4
-
Participating Party shall adopt the
Non-participating Party’s comments and recommendations during
the litigation except to the extent they may materially impact the
Participating Party’s commercial best interests, as
determined by the Participating Party. In any such infringement
action or claim brought, the Non-participating Party shall upon the
Participating Party’s request, cooperate with the
Participating Party in all respects, and make available to the
Participating Party all relevant information and witnesses who are
employees or within the control of the Non-participating Party. To
the extent necessary, each Party agrees to be joined as a party in
any litigation where it is an indispensable party.
ARTICLE 5
LIMITED WARRANTY AND INDEMNIFICATION
5.1. Limited Warranty .
|